Sabby group discloses 9.56% Revelation Biosciences (REVB) ownership
Rhea-AI Filing Summary
Revelation Biosciences, Inc. is the subject of a Schedule 13G reporting that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz together beneficially own 605,702 shares of its common stock, representing 9.56% of the class as of the event date of 12/31/2025. The filing shows these shares are held with shared voting and dispositive power and no sole voting or dispositive power. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Revelation Biosciences.
Positive
- None.
Negative
- None.
Insights
Sabby entities report a passive 9.56% stake in Revelation Biosciences.
The Schedule 13G shows Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz collectively beneficially owning 605,702 common shares of Revelation Biosciences, equal to 9.56% of the outstanding class. All three reporting persons list zero sole voting and dispositive power and the same shared voting and dispositive power over these shares.
Because the stake is reported on a Schedule 13G rather than 13D, the group certifies that the position was not acquired to change or influence control of the company. That indicates a passive investment posture under the rules cited, although future intent would depend on any subsequent filings.
The date of the reportable event is 12/31/2025, giving investors a snapshot of ownership at that point in time. Any material changes in this 9.56% position, or a shift from a 13G to a 13D filing status in later periods, would typically be reflected in updated beneficial ownership disclosures.